We're enabling a better life for everyone living with a rare disease.

400 million people worldwide live with a rare disease.
Rarebase is tackling this overwhelming need using proven science and innovative high-throughput technology to achieve drug discovery at unprecedented speed and scale. Through our FUNCTIONTM platform, we are creating a portfolio of potential therapeutics for hundreds of diseases at once, at a fraction of the cost and time of traditional methods.
Meet the Function™️ platform

Drug discovery for thousands of genetic disorders in one unified platform.

The Function platform combines two unique data sets: large scale drug screens and genetic screens performed in neurons. The drug screen tests the effects of thousands of small molecules  on gene expression. The genetic screen measures changes in expression when disease causing genes are suppressed.

The combined data sets will be used to match potentially effective drugs to rare disorder genes. Our hope is that Function provides many therapeutic candidates that can be rapidly developed for patients living with neurological diseases.

The Function platform discovers drugs that address underlying disease biology, at scale.

We match genetic disorders with thousands of therapeutic candidates using our functional genomics screening platform.
Disease models
We create cell-based disease models directly from patients’ samples.
We test therapeutic candidates in patient cell models for therapeutic effects, such as making a functional gene copy compensate for a dysfunctional one.
We use validation data from the disease models to improve the Function platform’s predictions.

“Rarebase is pushing the limits of science and innovating a financial structure that allows patient organizations to directly support drug discovery.”

- Mike Graglia, Founder and Managing Director, SynGAP Research Fund

“Rarebase is stepping outside the traditional drug development pipeline and harnessing new technology and science that patient organizations like ours would never be able to utilize alone.”

- Sandra Sermone, Founder and President, ADNP Kids Research Foundation

We're in this together.

Rarebase collaborates with a growing number of rare disease focused patient organizations to apply the latest in drug discovery to genetic neurological diseases.
by recommendation
All of our patient organization relationships come from recommendations from current partners or connections from within the rare disease community.
Over 110 patients and their families affected by rare disease are actively participating in our research studies.
novel candidate in development
Rarebase is already developing its first novel neurodegeneration candidate in partnership with a patient organization. This target is conserved across multiple neurodegenerative diseases.

For us, it’s personal.

We're a passionate team focused on pushing the boundaries of translational medicine to help develop new therapies for medically underserved patient communities.
Onno Faber
Co-founder and CEO
Omid Karkouti
Co-founder and COO
Chris Moxham, PhD
Chief Scientific Officer
Elizabeth Iorns, PhD
Scientific Founder & Advisor
Nicole Perfito, PhD
VP of Research Operations
Natalie Downs, MS, CGC
Senior Project Manager
Sabine Topka, PhD
Director of Discovery Biology
Carrie Rich
Chief Partnerships Officer
Riley Parsons
Senior Software Engineer
Clayton Mellina
Director of Software Engineering
Arun Mahadevan, PhD
Senior Scientist I, Phenotypic Screening
Joe Bellucci, PhD
Director of High Throughput Biology
Alex Guin, PhD
Bioinformatics Engineer
Ursula Leone Haditsch, PhD
Director of iPSC Cell Modeling
Amanda Faubel
Project Manager
Gabriel Rivera Del Toro
Research Associate I, Discovery Biology
Kristine Hashimoto
Partnerships Associate
Deanna Wong
Senior Operations Manager
Christian Markopoulos
Senior Scientist II, Phenotypic Screening
Long McFarlin
Senior Scientist I, iPSC Cell Modeling
Eric Yeager
Associate Director, Facilities
Jackie Van Siclen
Research Associate II, iPSC Cell Modeling
Mo Rahman
Scientific Advisor (Bioinformatics)
Michael Genin, PhD
Scientific Advisor (Drug Development)
Meg Wood
Strategic Advisor (Partnerships)
Matt Deardorff, MD PhD
Scientific Advisor (Clinical Genetics)
Matt Might, PhD
Scientific Advisor
Matt De Silva
Carolina Garcia Rizo, PhD

We’d love to hear from you. Let’s talk.

How did you hear about us?
Thank you! Your submission has been received! Someone from our team will reach out to you shortly.
Oops! Something went wrong while submitting the form.
Photography by: Ceridwen Hughes